Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 16/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MST1R | Q04912 | 2/20 | 0.35 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4396025 | 0.91 | MET (0.48) | METKCNH2MST1RCSF1RPTGS2 | |
| SCHEMBL10176091 | 0.89 | MET (0.52) | METKCNH2MST1R | |
| SCHEMBL4389280 | 0.80 | MET (0.52) | METKCNH2MST1R | |
| SCHEMBL397663 | 0.74 | MET (0.52) | METKCNH2MST1RCSF1R | |
| SCHEMBL397631 | 0.74 | MET (0.52) | METKCNH2MST1R | |
| SCHEMBL2448211 | 0.71 | MET (0.56) | METKCNH2MST1R | |
| SCHEMBL4297592 | 0.70 | MET (0.58) | METKCNH2MST1R | |
| SCHEMBL12443328 | 0.70 | MET (0.50) | METKCNH2MST1R | |
| SCHEMBL2450541 | 0.70 | MET (0.55) | METKCNH2MST1R | |
| SCHEMBL2360790 | 0.68 | MET (0.53) | METKCNH2MST1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049494-B1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8222269-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222269-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8101603-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101603-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090203684-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2009-08-13 | — | — | US | disclosed |
| US-20090203684-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2009-08-13 | — | — | US | disclosed |
| US-20090012076-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2009-01-08 | — | — | US | disclosed |
| US-20090012076-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2009-01-08 | — | — | US | disclosed |
| WO-2008008310-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012076-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, MET | MET 3/4885KCNH2 3873/4885MST1R 181/4885 |
| US-20090203684-A1 | Tyrosine kinase inhibitors | ABL1, MET, ERBB2 | MET 2/4885KCNH2 3869/4885MST1R 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.